Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Prostatic Neoplasms, Castration-Resistant Clinical Trial

— LACOG 1818  

Official title:

Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04962919
• Other study ID #: LACOG 1818
• Status: Active, not recruiting
• Start date: January 14, 2020
• Est. completion date: July 1, 2024

Study information

• Verified date: March 2024
• Source: Latin American Cooperative Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 584
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Exclusion Criteria:

• Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;

• Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Related Conditions & MeSH terms

• Prostatic Neoplasms
• Prostatic Neoplasms, Castration-Resistant

Locations

Country	Name	City	State
Brazil	CPO Pucrs	Porto Alegre	RS
Brazil	Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO	Santo André	São Paulo
Brazil	A.C.Camargo Cancer Center	São Paulo
Brazil	BP - A Beneficência Portuguesa de São Paulo	São Paulo
Brazil	Centro Paulista de Oncologia	São Paulo	SP
Brazil	Hospital Santa Marcelina	São Paulo
Brazil	Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central	São Paulo
Brazil	Sírio Libanês	São Paulo	SP

Sponsors (1)

Lead Sponsor	Collaborator
Latin American Cooperative Oncology Group

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.		December of 2017
Secondary	To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;		December of 2017
Secondary	To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;		December of 2017
Secondary	To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;		December of 2017
Secondary	To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;		December of 2017
Secondary	To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;		December of 2017
Secondary	To describe the rates of skeletal-related complications		December of 2017
Secondary	To describe the rate of admissions		December of 2017
Secondary	To describe the number of lines of treatment that patients have undergone		December of 2017
Secondary	To describe the presence or absence of treatments bone-directed		December of 2017